​

Moderna (MRNA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MRNA Stock Forecast

Moderna (MRNA) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $47.50, with a high of $50.00 and a low of $45.00. This represents a 73.67% increase from the last price of $27.35.

- $30 $60 $90 $120 $150 High: $50 Avg: $47.5 Low: $45 Last Closed Price: $27.35

MRNA Stock Rating

Moderna stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (47.37%), 9 Hold (47.37%), 1 Sell (5.26%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 1 9 9 Strong Sell Sell Hold Buy Strong Buy

MRNA Price Target Upside V Benchmarks

TypeNameUpside
StockModerna73.67%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts--18
Avg Price Target--$98.50
Last Closing Price$27.35$27.35$27.35
Upside/Downside--260.15%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2515171327
May, 2515171327
Apr, 2515171327
Mar, 2515161326
Feb, 2525151326
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 14, 2025Jessica FyeJ.P. Morgan$45.00$31.9240.98%64.53%
Feb 14, 2025Cory KaimovEvercore ISI$50.00$31.9256.64%82.82%
Nov 18, 2024Edward TenthoffPiper Sandler$69.00$37.2785.14%152.29%
Nov 18, 2024Yifeng LiuHSBC$58.00$84.93-31.71%112.07%
Oct 17, 2024Courtney BreenBernstein$55.00$57.46-4.28%101.10%
Oct 14, 2024Michael YeeJefferies$55.00$57.73-4.73%101.10%
Sep 13, 2024Edward TenthoffPiper Sandler$115.00$69.6865.04%320.48%
Sep 13, 2024Luca IssiRBC Capital$75.00$69.687.63%174.22%
Sep 13, 2024Leah Rush CannLoop Capital Markets$238.00$69.68241.56%770.20%
Sep 12, 2024Michael YeeJefferies$65.00$69.68-6.72%137.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024Evercore ISIReducedowngrade
Dec 10, 2024HSBCHoldBuyupgrade
Nov 22, 2024JefferiesHoldHoldhold
Nov 18, 2024Piper SandlerOverweightOverweighthold
Oct 24, 2024Piper SandlerOverweightOverweighthold
Oct 21, 2024Cowen & Co.HoldHoldhold
Oct 17, 2024BernsteinMarket Performinitialise
Oct 15, 2024Sandler O'NeilUnderperformUnderperformhold
Oct 14, 2024JefferiesHoldHoldhold
Sep 13, 2024Sandler O'NeillSector PerformSector Performhold

Financial Forecast

EPS Forecast

$-20 $-9 $2 $13 $24 $35 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.96$30.28$21.22$-12.34$-9.27----
Avg Forecast$-1.57$27.27$21.26$-13.46$-9.12$-8.91$-6.91$-4.90$-2.64
High Forecast$-1.29$34.01$25.98$-11.27$-8.03$-6.72$-2.06$1.34$-1.89
Low Forecast$-1.96$22.35$17.34$-15.66$-10.29$-10.29$-8.49$-7.46$-3.35
Surprise %24.84%11.04%-0.19%-8.32%1.64%----

Revenue Forecast

$0 $5B $10B $15B $20B $25B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$274.49M$17.74B$19.26B$6.85B$3.24B----
Avg Forecast$534.89M$18.02B$19.13B$6.47B$3.23B$2.56B$3.09B$4.14B$5.30B
High Forecast$636.62M$21.45B$22.40B$6.84B$3.35B$3.16B$3.16B$4.27B$6.40B
Low Forecast$460.65M$15.52B$16.42B$6.17B$3.15B$2.27B$3.02B$4.01B$4.14B
Surprise %-48.68%-1.57%0.70%5.92%0.32%----

Net Income Forecast

$-10B $-4B $2B $8B $14B $20B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-747.06M$12.20B$8.36B$-4.71B$-3.56B----
Avg Forecast$-607.66M$11.55B$13.15B$-4.71B$-3.50B$-3.53B$-2.71B$-1.97B$-1.01B
High Forecast$-486.13M$13.86B$15.78B$-3.77B$-3.07B$-2.57B$-787.35M$510.78M$-721.88M
Low Forecast$-729.20M$9.24B$10.52B$-5.66B$-3.93B$-3.93B$-3.24B$-2.85B$-1.28B
Surprise %22.94%5.65%-36.42%-1.80%----

MRNA Forecast FAQ

Is Moderna stock a buy?

Moderna stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 9 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Moderna is a favorable investment for most analysts.

What is Moderna's price target?

Moderna's price target, set by 19 Wall Street analysts, averages $47.5 over the next 12 months. The price target range spans from $45 at the low end to $50 at the high end, suggesting a potential 73.67% change from the previous closing price of $27.35.

How does Moderna stock forecast compare to its benchmarks?

Moderna's stock forecast shows a 73.67% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Moderna over the past three months?

  • June 2025: 3.70% Strong Buy, 18.52% Buy, 62.96% Hold, 3.70% Sell, 11.11% Strong Sell.
  • May 2025: 3.70% Strong Buy, 18.52% Buy, 62.96% Hold, 3.70% Sell, 11.11% Strong Sell.
  • April 2025: 3.70% Strong Buy, 18.52% Buy, 62.96% Hold, 3.70% Sell, 11.11% Strong Sell.

What is Moderna’s EPS forecast?

Moderna's average annual EPS forecast for its fiscal year ending in December 2025 is $-8.91, marking a -3.88% decrease from the reported $-9.27 in 2024. Estimates for the following years are $-6.91 in 2026, $-4.9 in 2027, and $-2.64 in 2028.

What is Moderna’s revenue forecast?

Moderna's average annual revenue forecast for its fiscal year ending in December 2025 is $2.56B, reflecting a -20.77% decrease from the reported $3.24B in 2024. The forecast for 2026 is $3.09B, followed by $4.14B for 2027, and $5.3B for 2028.

What is Moderna’s net income forecast?

Moderna's net income forecast for the fiscal year ending in December 2025 stands at $-3.53B, representing a -0.86% decrease from the reported $-3.561B in 2024. Projections indicate $-2.713B in 2026, $-1.966B in 2027, and $-1.01B in 2028.